Issue link: http://sarahcannon.uberflip.com/i/1492123
0208/23SCB003/R6 In 2022, Sarah Cannon Research Institute (SCRI) formed a joint venture with US Oncology Research (USOR) to enhance clinical trial access and availability across the country. *Presentations highlighted in blue represent research that was conducted across SCRI and the Sarah Cannon Transplant & Cellular Therapy Network, a Network of nine FACT/ JACIE accredited transplant centers across HCA Healthcare. 4 FRIDAY, FEBRUARY 17 TH 11:45am - 5:00pm Eastern Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 3:45 - 5:15pm 4:00 - 4:15pm Cypress 3 Oral 44 Primary Analysis (PA) Results from the Randomized, Phase 3 TRANSFORM Study of Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Abramson JS, Solomond SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Kamdar M Oral Abstract - Session G: Engineered Immune Cells - Session II 4:15 - 5:00pm 4:15 - 4:30pm Grand 8A Oral 85 Sustaining a Median of 60 Minutes or Less for Time to First Antibiotic for Febrile Neutropenic Patients Using the Oncology ALERT Program across Multiple Network Emergency Departments Stentz J, Cox T, Carelock T, Bedi N, Bureson C, Chewning A, Meadors S, Nichols M, Slaughter C, Majhail NS (ADMIN) Best Abstracts SATURDAY, FEBRUARY 18 TH 10:15am - 5:30pm Eastern Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title Author List *Legacy SCRI and Sarah Cannon Transplant & Cellular Therapy Network authors in blue, lead authors Bold *Legacy USOR authors in orange, lead authors Bold Session Name 10:15 - 11:45am 11:00 - 11:15am Cypress 3 Oral 64 Access Barriers for Anti-CD19+ Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Non- Hodgkin Lymphoma (NHL) across a Large Community Transplant and Cellular Therapy Network Battiwalla M, Tees M, Flinn IW, Pantin J, Berdeja J, Gregory T, Maris M, Bhushan V, Vance E, Mathews J, Bachier C, Shaughnessy PJ, Ramakrishnan A, Malik S, Mori S, Billups R, Blunk B, LeMaistre CF, Majhail NS Oral Abstract - Session J: Intersectionality, Diversity, and Inclusion & Health Services 10:15 - 11:45am Sabal Oral Chairman Frangoul H Oral Abstract - Session L: Post-transplant Complications - From Engraftment Failure to Vascular and Immune and Infectious Toxicities 12:30 - 2:30pm 1:40 - 1:55pm Crystal NPQ Oral NA ASTCT/NMDP ACCESS Initiative: Poverty Committee Update Majhail NS (ASTCT) ASTCT/NMDP Access Workshop 4:30 - 5:30pm 4:30 - 4:45pm Cypress 3 Oral LBA 1 Idecabtagene Vicleucel (ide- cel) Versus Standard Regimens in Patients (pts) with Triple- Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Karmma-3 a Phase (Ph) 3 Randomized Controlled Trial (RCT) Giralt S, Ailawadhi S, Arnulf B, Patel KK, Cavo M, Nooka A, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre- Kontula L, Wu F, Piasecki J, Cook M, Rodriguez-Otero P Late Breaking Abstracts TANDEM TRANSPLANTATION AND CELLULAR THERAPY MEETINGS 2023 PRESENTATION CALENDAR
